New approaches for identifying and testing potential new anti-asthma agents

Amelia Licari, Riccardo Castagnoli, Ilaria Brambilla, Alessia Marseglia, Maria Angela Tosca, Gian Luigi Marseglia, Giorgio Ciprandi

Research output: Contribution to journalReview article

Abstract

INTRODUCTION: Asthma is a chronic disease with significant heterogeneity in clinical features, disease severity, pattern of underlying disease mechanisms, and responsiveness to specific treatments. While the majority of asthmatic patients are controlled by standard pharmacological strategies, a significant subgroup has limited therapeutic options representing a major unmet need. Ongoing asthma research aims to better characterize distinct clinical phenotypes, molecular endotypes, associated reliable biomarkers, and also to develop a series of new effective targeted treatment modalities. Areas covered: The expanding knowledge on the pathogenetic mechanisms of asthma has allowed researchers to investigate a range of new treatment options matched to patient profiles. The aim of this review is to provide a comprehensive and updated overview of the currently available, new and developing approaches for identifying and testing potential treatment options for asthma management. Expert opinion: Future therapeutic strategies for asthma require the identification of reliable biomarkers that can help with diagnosis and endotyping, in order to determine the most effective drug for the right patient phenotype. Furthermore, in addition to the identification of clinical and inflammatory phenotypes, it is expected that a better understanding of the mechanisms of airway remodeling will likely optimize asthma targeted treatment.

Original languageEnglish
Pages (from-to)51-63
Number of pages13
JournalExpert Opinion on Drug Discovery
Volume13
Issue number1
DOIs
Publication statusPublished - Jan 2018

    Fingerprint

Keywords

  • Airway Remodeling/drug effects
  • Animals
  • Anti-Asthmatic Agents/pharmacology
  • Asthma/diagnosis
  • Biomarkers/metabolism
  • Chronic Disease
  • Drug Design
  • Humans
  • Molecular Targeted Therapy
  • Phenotype

Cite this